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Summary
Background Dexamethasone improves outcome for some patients with bacterial meningitis, but not others. We aimed 
to identify which patients are most likely to beneﬁ t from dexamethasone treatment.  
Methods We did a meta-analysis of individual patient data from the randomised, double-blind, placebo-controlled 
trials of dexamethasone for bacterial meningitis in patients of all ages for which raw data were available. The pre-
determined outcome measures were death at the time of ﬁ rst follow-up, death or severe neurological sequelae at 
1 month follow-up, death or any neurological sequelae at ﬁ rst follow-up, and death or severe bilateral hearing loss at 
ﬁ rst follow-up. Combined odds ratios (ORs) and tests for heterogeneity were calculated using conventional 
Mantel-Haenszel statistics. We also did exploratory analysis of hearing loss among survivors and other exploratory 
subgroup analyses by use of logistic regression. 
Findings Data from 2029 patients from ﬁ ve trials were included in the analysis (833 [41·0%] aged <15 years). HIV 
infection was conﬁ rmed or likely in 580 (28·6%) patients and bacterial meningitis was conﬁ rmed in 1639 (80·8%). 
Dexamethasone was not associated with a signiﬁ cant reduction in death (270 of 1019 [26·5%] on dexamethasone 
vs 275 of 1010 [27·2%] on placebo; OR 0·97, 95% CI 0·79–1·19), death or severe neurological sequelae or bilateral 
severe deafness (42·3% vs 44·3%; 0·92, 0·76–1·11), death or any neurological sequelae or any hearing loss (54·2% 
vs 57·4%; 0·89, 0·74–1·07), or death or severe bilateral hearing loss (36·4% vs 38·9%; 0·89, 0·73–1·69). However, 
dexamethasone seemed to reduce hearing loss among survivors (24·1% vs 29·5%; 0·77, 0·60–0·99, p=0·04). 
Dexamethasone had no eﬀ ect in any of the prespeciﬁ ed subgroups, including speciﬁ c causative organisms, pre-
dexamethasone antibiotic treatment, HIV status, or age. Pooling of the mortality data with those of all other published 
trials did not signiﬁ cantly change the results. 
Interpretation Adjunctive dexamethasone in the treatment of acute bacterial meningitis does not seem to signiﬁ cantly 
reduce death or neurological disability. There were no signiﬁ cant treatment eﬀ ects in any of the prespeciﬁ ed 
subgroups. The beneﬁ t of adjunctive dexamethasone for all or any subgroup of patients with bacterial meningitis 
thus remains unproven.
Funding Wellcome Trust UK. 
Introduction
The yearly incidence of bacterial meningitis is estimated 
to be 2·6–6·0 cases per 100 000 in Europe and might be 
ten times higher in less developed countries.1–4 
Experimental models have shown that outcome is related 
to the severity of the inﬂ ammatory process in the 
subarachnoid space, and treatment with corticosteroids 
results in a reduction of the inﬂ ammatory response and 
improved outcome.5–7 These ﬁ ndings have prompted 
several randomised controlled trials of corticosteroids for 
bacterial meningitis.8 Initial results suggested that the 
main beneﬁ cial eﬀ ect of the corticosteroid dexamethasone 
was to reduce the risk of hearing loss in children with 
Haemophilus inﬂ uenzae type b meningitis.9 Additional 
data extended the likely beneﬁ t to those with Streptococcus 
pneumoniae meningitis.10 In 2004, a meta-analysis of ﬁ ve 
randomised controlled trials showed that treatment with 
corticosteroids reduced both mortality and neurological 
sequelae in adults with bacterial meningitis, without 
detectable adverse eﬀ ects.11 Subsequently, a Cochrane 
meta-analysis of data from 20 randomised controlled 
trials and involving 2750 people showed an overall 
mortality beneﬁ t and a reduction in neurological sequelae 
in patients treated with adjuvant corticosteroids.8 
However, three large randomised controlled trials 
published after this analysis showed conﬂ icting results.12–14 
Adjunctive corticosteroids seem to beneﬁ t some patients 
with bacterial meningitis but not others, and how to 
select patients who are likely to beneﬁ t is unclear. Our 
aim was to address this question with a meta-analysis of 
data from ﬁ ve major trials for which individual patient 
data were available.  
Methods
Study selection
Relevant trials were identiﬁ ed previously as part of a 
Cochrane review (ﬁ gure 1).8 Individual patient data from 
ﬁ ve randomised, double-blind, placebo-controlled trials 
of dexamethasone for bacterial meningitis published 
since 2001 were included in the analysis;12–16 individual 
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patient data could not be acquired from the older 
trials.17–27 The characteristics of the included studies are 
shown in table 1.
The study from South America used a 2×2 design to 
randomly assign children with bacterial meningitis to 
dexamethasone plus glycerol, dexamethasone plus 
placebo, glycerol plus placebo, or placebo plus placebo.12 
Data were available from children who were assigned 
dexamethasone plus placebo or placebo only but not 
from those who were given glycerol. During the study, 
the randomisation schedule was altered from a ratio of 
two dexamethasone per three placebo (randomisation 
schedule 1) to one dexamethasone per one placebo 
(randomisation schedule 2). Therefore, analyses from 
this study were stratiﬁ ed according to randomisation 
schedule. The study in Malawian adults used a 2×2 
design to randomly assign patients to dexamethasone or 
placebo and to intravenous or intramuscular ceftriaxone.14 
In all studies, patients were enrolled on the basis of 
clinically suspected bacterial meningitis and CSF criteria. 
All the studies used computer-generated randomisation 
to allocate patients to dexamethasone or placebo. 
Treatment concealment was adequate in all studies.
Deﬁ nitions and outcome measures
The members of the study group met in October, 2006, 
and September, 2007, to discuss data sharing and the 
analysis plan, including the deﬁ nitions of subgroups, 
which were speciﬁ ed before the data were collated, the 
ﬁ nal database created, and the analysis started. The 
principal investigators provided the raw data, which were 
checked by a statistician (PQT). Inconsistencies and 
outlying data were clariﬁ ed with the principal investigators 
and resolved from their raw data before the analysis. 
15 data ﬁ elds for each patient were selected for the 
analyses. The dataset included prognostic factors for 
unfavourable outcome and potential modiﬁ ers of the 
treatment eﬀ ect of dexamethasone, such as antibiotic 
treatment before admission, HIV infection, and 
malnutrition.1,3 Deﬁ nitions were agreed during the two 
study-group meetings. Values for continuous variables 
were reassigned into categories. Exposure to antibiotics 
before randomisation was deﬁ ned by administration of 
eﬀ ective oral or intravenous antibiotics within 48 h 
before the ﬁ rst dose of study drug was received. 
Malnutrition was deﬁ ned by individual investigators: 
patients who were not assessed were categorised 
according to the local prevalence of malnutrition. HIV 
tests were not done on every patient and an assessment 
was made of the likelihood of HIV infection based on 
local epidemiology. All untested Malawian adults were 
deﬁ ned as likely to be HIV positive. No assumption was 
made for untested Malawian children. All other 
untested adults or children were deﬁ ned as likely to be 
HIV negative. Impairment of consciousness was 
categorised by use of the Glasgow coma scale or the 
Blantyre coma score (table 2). The causative pathogen 
was deﬁ ned by CSF microscopy, CSF or blood culture, 
PCR, or latex agglutination. 
The predetermined outcome measures were death at the 
time of ﬁ rst follow-up; death or severe neurological 
sequelae (including severe bilateral hearing loss) at 
1 month follow-up; death or any neurological sequelae 
(including any degree of hearing loss) at ﬁ rst follow-up; 
and death or severe bilateral hearing loss at ﬁ rst follow-up. 
The number of studies that contributed to each outcome is 
shown by degrees of freedom (df=number of studies 
minus 1). Additionally, as part of a post-hoc exploratory 
analysis and to analyse every possible endpoint of interest, 
we analysed hearing loss of any degree among survivors. 
The severity of neurological sequelae in the adult studies 
was deﬁ ned using the Glasgow outcome score or the 
modiﬁ ed Rankin scale.28,29 In the paediatric studies, severe 
neurological disability was deﬁ ned as blindness, 
quadraparesis, hydrocephalus requir ing a shunt, or severe 
psychomotor retardation. Hearing loss was categorised as 
moderate or severe according to deﬁ nitions used in the 
individual studies. 
Statistical analysis
All analyses were stratiﬁ ed according to study site 
(including two strata from the South American study) to 
account for any possible centre eﬀ ect, including 
diﬀ erences in mortality between centres. If appropriate, 
analyses were also stratiﬁ ed according to the baseline 
variable of interest. Combined odds ratios (ORs) and 
tests for heterogeneity were calculated using conventional 
Mantel-Haenszel statistics. We also used exploratory 
analyses with logistic regression. The main purpose of 
the analysis was to establish whether dexamethasone had 
a diﬀ erential eﬀ ect in diﬀ erent subgroups of patients; 
hence, heterogeneity between the subgroups (I² values) 
with signiﬁ cance levels were calculated for each subgroup 
analysis. Tests for heterogeneity were calculated without 
18 studies identiﬁed from Cochrane review
5 studies with individual patient data available
(2447 patients)
2029 individual patient records in meta-analysis 
418 patients from South America
with unavailable data
4 trials published since 
Cochrane review
17 trials without individual 
patient data available or
studies other than trials
Figure 1: Literature search
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allowing for multiple comparisons, to increase the 
sensitivity of detecting any evidence of between-subgroup 
heterogeneity. To maximise the power of ﬁ nding 
signiﬁ cant heterogeneity, missing values were removed, 
except where indicated, from the subgroup analyses. A 
continuity correction was made for zero events. 
Signiﬁ cance tests, with the appropriate degrees of 
freedom, were calculated to test for possible heterogeneity 
between studies for each subgroup analysis. 
To calculate the combined ORs for death from studies 
included in the Cochrane reviews but not otherwise 
included in the present study, results available from the 
published literature were combined by use of conventional 
Mantel-Haenszel statistics. Calculation of combined ORs 
and 95% CIs, tests of heterogeneity between studies, and 
logistic regression analyses were done by use of STATA 
version 10. 
Role of the funding source
The study sponsors had no role in the study design, 
collection, analysis, and interpretation of the data, or the 
decision to submit the manuscript for publication. 
T E Peto had full access to all data in the study. All authors 
approved and were responsible for submission of the 
manuscript.
Results
The baseline characteristics were similar in placebo and 
dexamethasone groups within the ﬁ ve studies (table 2). 
1019 (50·2%) patients received dexamethasone and 1010 
(49·8%) patients received placebo. 833 (41·1%) patients 
were less than 15 years old, of whom 415 received 
dexamethasone and 418 received placebo. 1196 adults 
(aged ≥15 years) were included, of whom 604 (50·5%) 
received dexamethasone and 592 (49·5%) received 
placebo. The ages of ﬁ ve patients were unknown.
HIV co-infection was conﬁ rmed in 549 (41·5%) of 
1322 patients tested, of whom 391 (71·4%) were adults 
and 158 (28·8%) were children. An HIV test was not 
done in 707 (34·8%) patients but, on the basis of 
epidemiological risk, was judged likely to be positive in 
31 untested adults from Malawi and negative in adults 
from Europe and children from South America. No 
assumption was made about 139 untested children 
from Malawi. In total, 286 conﬁ rmed or likely HIV-
infected patients received dexamethasone and 
294 received placebo. 
The diagnosis of bacterial meningitis was 
microbiologically conﬁ rmed in 1639 (80·8%) patients 
and was most frequently caused by S pneumoniae 
(759 cases), H inﬂ uenzae (297 cases), and Neisseria 
meningitidis (239 cases). The most common causative 
bacteria per study were as follows: Europe, N meningitis 
(38%);16 Malawi (children), S pneumoniae (40%);15 
Vietnam, Streptococcus suis (32%);13 Malawi (adults), 
S pneumoniae (59%);14 and South America, H inﬂ uenzae 
(47%).12 Mortality in the placebo groups diﬀ ered 
substantially between studies: 15% in Europe, 31% in 
Malawian children, 12% in Vietnam, 53% in Malawian 
adults, and 16% in South America.
Dexamethasone was not associated with a signiﬁ cant 
reduction in death, death or severe neurological sequelae 
(including severe bilateral hearing loss), death or any 
neurological sequelae (including any hearing loss), or 
death or severe bilateral hearing loss, if all patients were 
included in the analysis (table 3). However, hearing loss (of 
any severity) in survivors was less common in the 
dexamethasone group (162 [24·1%] of 672 vs 195 [29·5%] of 
660; OR 0·77 [95% CI 0·60–0·99], p=0·04). 
The subgroup analyses for all outcome measures are 
shown in ﬁ gures 2 and 3, and the webappendix. Duration 
of symptoms before treatment, severity of coma at start 
of treatment, whether dexamethasone was given before 
or after antibiotics, and HIV infection status did not 
signiﬁ cantly inﬂ uence treatment response. Dexa metha-
sone was more eﬀ ective in patients aged older than 
Study 
period
Patients 
(n)
Age Inclusion criteria Dexamethasone dose Empirical antibiotic* Primary outcome
Europe16 1992–2001 301 >16 years Clinically suspected BM 
plus CSF criteria
10 mg four times daily 
for 4 days
Intravenous amoxicillin 2 g every 4 h 
(77% of patients†)
Unfavourable outcome (deﬁ ned by a 
Glasgow outcome score of 1–4) at 8 weeks
Malawi 
(child)15
1997–2001 598 2 months to 
13 years
Clinically suspected BM 
plus CSF criteria
0·4 mg/kg twice daily 
for 2 days
Intravenous benzylpenicillin 
200 000 IU/kg every 24 h plus 
chloramphenicol 100 mg/kg every 24 h
Death at 1 month
Vietnam13 1996–2005 429 >14 years Clinically suspected BM 
plus CSF criteria
0·4 mg/kg twice daily 
for 4 days
Intravenous ceftriaxone 2 g every 12 h Death at 1 month
Malawi 
(adult)14‡
2002–2005 465 >15 years Clinically suspected BM 
plus CSF criteria
16 mg twice daily for 
4 days
Intravenous or intramuscular 
ceftriaxone 2 g every 12 h
Death at 1 month
South 
America12§
1996–2003 236 2 months to 
16 years
Clinically suspected BM 
plus CSF or blood criteria
0·15 mg/kg four times 
daily for 2 days
Intravenous ceftriaxone 
80–100 mg/kg every 24 h
Death, severe neurological sequelae, or 
audiological sequelae at hospital discharge
BM=bacterial meningitis. *Dexamethasone was given before or with the ﬁ rst dose of per-protocol parenteral antibiotic in all ﬁ ve studies. †23% of patients received other antibiotic treatment. ‡2×2 design with 
patients randomly assigned to dexamethasone or placebo and to intravenous or intramuscular ceftriaxone. §2×2 design with patients randomly assigned to dexamethasone plus glycerol, dexamethasone plus 
placebo, placebo plus glycerol, or placebo plus placebo; patients assigned to receive glycerol with either dexamethasone or placebo were excluded from the individual patient data meta-analysis; data from this 
trial were analysed as two strata according to randomisation schedule.   
Table 1: Characteristics of the ﬁ ve studies included in the analysis
See Online for webappendix
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55 years in analyses of death (OR 0·41 [95% CI 0·20–0·84], 
p=0·01), death or severe neurological sequelae (OR 0·53 
[0·30–0·84], p=0·03), and death or any neurological 
sequelae (OR 0·56 [0·31–1·00], p=0·05). However, there 
was no clear evidence of heterogeneity between the 
diﬀ erent age groups (death, χ²=6·9, 3 df, p=0·07, 
I² 54·5%; death or severe neurological sequelae, χ²=6·6, 
3 df, p=0·09, I²=53·4%; death or any neurological 
sequelae, χ²=4·4, 3 df, p=0·23, I²=30·3%). Further 
exploratory analyses, using age as a continuous variable, 
Europe16 
(n=301)
Malawi (child)15 
(n=598)
Vietnam13 
(n=429)
Malawi (adult)14 
(n=465)
South America12 Total (n=2029) Dexamethasone 
(n=1019)
Placebo 
(n=1010)
Randomisation 
schedule 1  
(n=126)
Randomisation 
schedule 2 
(n=110)
Age (years)
<5 0 429 0 0 117 90 636 316 320
5–15 1 168 0 2 9 17 197 99 98
16–55 198 0 322 447 0 0 967 490 477
>55 102 0 106 16 0 0 224 112 112
Unknown 0 1 1 0 0 3 5 2 3
Sex
Men 169 (56%) 337 (56%) 315 (73%) 230 (50%) 73 (58%) 63 (57%) 1187 (58%) 601 (59%) 586 (58%)
Symptoms <48 h
Yes 233 (77%) 266 (44%) 121 (28%) 121 (26%) 91 (72%) 93 (84%) 925 (46%) 471 (46%) 454 (45%)
Unknown 2 (1%) 2 (0·3%) 2 (0·5%) 5 (1%) 15 (12%) 9 (8%) 35 (2%) 17 (2%) 18 (2%)
Prior antibiotic exposure 
Yes 5 (2%) 127 (21%) 238 (55%) 123 (26%) 46 (36%) 35 (32%) 574 (28%) 281 (28%) 293 (29%)
Unknown 0 0 0 0 14 (11%) 11 (10%) 25 (1%) 9 (1%) 16 (2%)
Malnutrition
Yes .. 307 (52%) 46 (11%) .. 6 (5%) 7 (6%) 366 (18%) 187 (18%) 179 (18%)
No .. 288 (48%) 375 (87%) .. 59 (47%) 41 (37%) 763 (38%) 380 (37%) 383 (38%)
Not assessed (likely yes) .. .. 8 (2%) .. 61 (48%) 62 (56%) 476 (23%) 237 (23%) 239 (24%)
Not assessed (likely no) 301 3 (0·5%) .. .. .. .. 424 (21%) 215 (21%) 209 (21%)
HIV infection*
Positive/tested 0/0 157/459 (34%) 3/429 (1%) 389/434 (90%) 0/0 0/0 549/1322 (42%) 269/663 (41%) 280/659 (42%)
Heart rate
≥120 beats per min 42 (14%) 513 (86%) 58 (14%) 118 (25%) 75 (60%) 56 (51%) 862 (42%) 430 (42%) 432 (43%)
Unknown 2 (1%) 8 (1%) 12 (3%) 8 (2%) 5 (4%) 7 (6%) 42 (2%) 19 (2%) 23 (2%)
Level of consciousness†
Normal 103 (34%) 219 (37%) 147 (34%) 84 (18%) 23 (18%) 17 (16%) 593 (29%) 288 (28%) 305 (30%)
Mild impairment 102 (34%) 168 (28%) 145 (34%) 162 (35%) 57 (45%) 65 (59%) 699 (34%) 349 (34%) 350 (35%)
Moderate impairment 68 (23%) 125 (21%) 88 (20%) 129 (28%) 25 (20%) 17 (16%) 452 (22%) 239 (23%) 213 (21%)
Severe impairment 28 (9%) 84 (14%) 46 (11%) 90 (19%) 16 (13%) 11 (10%) 275 (14%) 137 (13%) 138 (14%)
Unknown 0 2 (0·3%) 3 (1%) 0 5 (4%) 0 10 (0·5%) 6 (0·6%) 4 (0·4%)
Haemoglobin
<10 g/dL 7 (2%) 373 (62%) 14 (3%) 181 (39%) 90 (71%) 73 (66%) 738 (36%) 367 (36%) 371 (37%)
Unknown 0 70 (12%) 36 (8%) 31 (7%) 6 (5%) 3 (3%) 148 (7%) 67 (7%) 79 (8%)
CSF white cell count (cells per μL)
0–99 8 (3%) 22 (4%) 7 (2%) 93 (20%) 7 (6%) 3 (3%) 140 (7%) 76 (7%) 64 (6%)
100–999 44 (15%) 172 (29%) 95 (22%) 186 (40%) 40 (32%) 27 (24%) 564 (28%) 286 (28%) 280 (28%)
1000–9999 166 (55%) 258 (43%) 253 (59%) 158 (34%) 55 (44%) 47 (43%) 937 (46%) 450 (44%) 487 (48%)
>10 000 78 (26%) 144 (24%) 72 (17%) 20 (4%) 16 (13%) 19 (17%) 349 (17%) 187 (18%) 162 (16%)
Unknown 5 (2%) 2 (0·3%) 2 (0·5%) 8 (2%) 8 (6%) 14 (13%) 39 (2%) 22 (2%) 17 (2%)
CSF glucose (mg/dL)‡
≤20 169 (56%) 475 (79%) 179 (42%) 332 (71%) 64 (51%) 61 (56%) 1280 (63%) 648 (64%) 632 (62%)
>20 122 (40%) 31 (5%) 248 (58%) 72 (16%) 53 (42%) 46 (42%) 572 (28%) 284 (28%) 288 (29%)
Unknown 10 (3%) 92 (15%) 2 (0·5%) 61 (13%) 9 (7%) 3 (3%) 177 (9%) 87 (8%) 90 (9%)
(Continues on next page)
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Europe16 
(n=301)
Malawi (child)15 
(n=598)
Vietnam13 
(n=429)
Malawi (adult)14 
(n=465)
South America12 Total (n=2029) Dexamethasone 
(n=1019)
Placebo 
(n=1010)
Randomisation 
schedule 1  
(n=126)
Randomisation 
schedule 2 
(n=110)
(Continued from previous page)
CSF protein (mg/dL)‡
≥250 195 (65%) 412 (69%) 191 (45%) 341 (73%) 23 (18%) 33 (30%) 1195 (59%) 588 (58%) 607 (60%)
<250 97 (32%) 26 (4%) 227 (53%) 33 (7%) 77 (61%) 73 (66%) 533 (26%) 283 (28%) 250 (25%)
Unknown 9 (3%) 160 (27%) 11 (2%) 91 (20%) 26 (20%) 4 (4%) 301 (15%) 148 (14%) 153 (15%)
Bacteria on CSF microscopy
Yes 215 (71%) 427 (71%) 249 (57%) 263 (57%) 74 (59%) 69 (63%) 1297 (64%) 641 (63%) 656 (65%)
Unknown 0 0 0 15 (3%) 34 (27%) 24 (22%) 73 (4%) 38 (4%) 35 (4%)
Causative pathogen
Streptococcus pneumoniae 112 (37%) 238 (40%) 77 (18%) 275 (59%) 22 (18%) 35 (32%) 759 (37%) 383 (38%) 376 (37%)
Neisseria meningitidis 115 (38%) 67 (11%) 29 (7%) 20 (4%) 4 (3%) 4 (4%) 239 (12%) 122 (12%) 117 (12%)
Haemophilus inﬂ uenzae 4 (1%) 170 (28%) 8 (2%) 3 (0·6%) 66 (52%) 46 (42%) 297 (15%) 135 (13%) 162 (16%)
Streptococcus suis .. .. 137 (32%) .. .. .. 137 (7%) 72 (7%) 65 (6%)
Other aerobic gram negative bacilli 3 (1%) 38 (6%) 21 (5%) 22 (5%) 3 (2%) 1 (1%) 88 (4%) 51 (5%) 37 (4%)
Other 27 (9%) 11 (2%) 68 (16%) 5 (1%) 3 (2%) 5 (4%) 119 (6%) 52 (5%) 67 (7%)
Deﬁ nitely not bacterial meningitis 0 0 11 (3%) 38 (8%) 1 (1%) 0 50 (2·5%) 28 (3%) 22 (2%)
Unknown (probable bacterial 
meningitis)
40 (13%) 74 (12%) 78 (18%) 102 (22%) 27 (21%) 19 (17%) 340 (17%) 176 (17%) 164 (16%)
Bacterial diagnosis conﬁ rmed 
microbiologically
261 (87%) 524 (88%) 340 (78%) 325 (70%) 98 (78%) 91 (83%) 1639 (81%) 815 (80%) 824 (81%)
Treatment allocation
Allocated to dexamethasone 
treatment
157 (52%) 305 (51%) 215 (50%) 233 (50%) 50 (40%) 59 (54%) 1019 (50%) .. ..
Data are number (%). *HIV serostatus was not available in patients in the European or South American trials; patients in these trials were assumed to be HIV negative. In the Vietnam trial, four untested patients 
were assumed to be HIV negative and in the Malawi adult trial, 31 untested patients were assumed to be HIV positive. In the Malawi paediatric trial, 139 (23%) patients were not tested and no assumption was 
made about their serostatus. Positive values only include patients tested and not those assumed to be positive. †Glasgow coma scale is categorised in adults as 15=normal, 11–14=mild impairment, 
8–10=moderate impairment, 3–7=severe impairment. Blantyre coma score is categorised as 5=normal, 3–4=mild impairment, 2=moderate impairment, 0–1=severe impairment. ‡The use of urine reagent strips 
in the trials from Malawi provided semi-quantitative estimates of CSF glucose and protein. Protein and glucose concentrations were measured with a urine dipstick (Multistix 8SG Bayer), which provided 
colour-coded results of (protein/glucose) negative (0/0 mg/dL); trace (<30/100 mg/dL); 1+ (31–100/101–250 mg/dL); 2+ (101–300/251–500 mg/dL); 3+ (301–2000/501–1000 mg/dL); 4+ (>2000/>1000 mg/dL). 
Table 2: Baseline characteristics of patients included in the analysis
Europe16 Malawi 
(child)15
Vietnam13 Malawi 
(adult)14
South America12 Overall Events/total (%) Test for heterogeneity
Randomisation 
schedule 1
Randomisation 
schedule 2
Dexamethasone Placebo χ2 (5 df) p I²
Death 0·44 
(0·20–0·96, 
0·03)
0·96 
(0·70–1·40, 
0·96)
0·82 
(0·45–1·51, 
0·53)
1·16 
(0·80–1·67, 
0·43)
1·46 
(0·63–3·37, 
0·37)
0·74 
(0·27–2·00, 
0·55)
0·97 
(0·79–1·19, 
0·75)
270/1019 
(26·5%)
275/1010 
(27·2%)
6·5 0·26 22·7%
Death or severe 
neurological sequelae or 
bilateral severe deafness
0·60 
(0·34–1·11, 
0·07)
1·20 
(0·87–1·66, 
0·28)
0·75 
(0·48–1·17, 
0·20)
1·02 
(0·69–1·50, 
0·93)
0·74 
(0·35–1·55, 
0·42)
0·74 
(0·33–1·67, 
0·52)
0·92 
(0·76–1·11, 
0·39)
424/1003 
(42·3%)
439/992 
(44·3%)
6·5 0·26 23·2%
Death or any 
neurological sequelae or 
any hearing loss
0·49 
(0·28–0·84, 
0·01)
1·02 
(0·74–1·42, 
0·89)
0·81 
(0·55–1·18, 
0·27)
1·03 
(0·67–1·56, 
0·91)
1·29 
(0·60–2·77, 
0·51)
0·84 
(0·39–1·79, 
0·65)
0·89 
(0·74–1·07, 
0·23)
541/999 
(54·2%)
567/988 
(57·4%)
7·1 0·22 29·3%
Death or severe 
bilateral hearing loss 
0·55 
(0·31–0·99, 
0·04)
1·03 
(0·73–1·45, 
0·86)
0·64 
(0·38–1·08, 
0·09)
1·08 
(0·73–1·58, 
0·70)
1·07 
(0·49–2·32, 
0·87)
0·70 
(0·29–1·69, 
0·43)
0·89 
(0·73–1·69, 
0·23)
343/942 
(36·4%)
363/934 
(38·9%)
6·2 0·28 19·8%
Any hearing loss in 
survivors
0·75 
(0·34–1·67, 
0·48)
0·80 
(0·51–1·28, 
0·35)
0·77 
(0·49–1·21, 
0·26)
0·80 
(0·44–1·45, 
0·45)
0·59 
(0·21–1·65, 
0·31)
0·81 
(0·30–2·14, 
0·66)
0·77 
(0·60–0·99, 
0·04)
162/672 
(24·1%)
195/660 
(29·5%)
0·3 1·00 0·0%
Data are OR (95% CI, p value) unless otherwise stated. OR values below 1 suggest a beneﬁ cial eﬀ ect of steroids.  
Table 3: Primary endpoints for each study and for all patients assigned to steroid therapy 
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did not show any consistent interaction between age and 
a treatment eﬀ ect (data not shown). There was also no 
eﬀ ect in a post-hoc analysis that restricted the study to 
patients treated with ceftriaxone (webappendix). 
The data were explored to identify evidence of 
heterogeneity between the studies. 23 subgroups were 
explored, each with ﬁ ve diﬀ erent endpoints. In patients 
with moderate CNS impairment on admission, there 
was some evidence of heterogeneity between three of 
the ﬁ ve endpoints. In the subgroup of patients with 
moderate CNS impairment on admission, there was 
evidence of beneﬁ t in death or severe neurological 
sequelae or bilateral hearing loss in the European study 
(OR 0·19 [95% CI 0·04–0·82], p=0·01), but also evidence 
of harm in the study of children in Malawi (OR 3·70 
[1·36–10·08], p=0·006). However, no evidence of 
Events/total (%) OR (95% CI) p Test for heterogeneity  
between studies 
Dexamethasone χ2 df p Placebo 
Favours dexamethasone   Favours placebo  
1 0·3 0·2 0·1 0·5 2 3 4 5 10 
Age (years)
<5 90/316 (28%) 87/320 (27%) 1·05 (0·74–1·48) 0·80 1·54 2 0·46
5–15 25/99 (25%) 28/98 (29%) 0·88 (0·46–1·67) 0·69 1·07 2 0·58
15–55 140/490 (29%) 128/477 (27%) 1·12 (0·81–1·54) 0·49 0·94 2 0·63
>55 15/112 (13%) 32/112 (29%) 0·41 (0·20–0·84) 0·01 1·51 2 0·47
Subtotal  (I2=54·5%, p=0·086)  0·98 (0·79–1·21)
Sex 
Female 128/431 (30%) 134/410 (33%) 0·90 (0·66–1·23) 0·52 4·62 5 0·46
Male 142/588 (24%) 141/599 (24%) 1·00 (0·75–1·33) 0·98 5·50 5 0·36
Subtotal  (I2=0·0%, p=0·625)  0·95 (0·77–1·18)
Preadmission symptoms <48 h
No 177/531 (33%) 167/538 (31%) 1·11 (0·84–1·45) 0·47 6·29 5 0·28
Yes 87/471 (18%) 103/454 (23%) 0·75 (0·54–1·05) 0·10 5·55 5 0·35
Subtotal  (I2=68·7%, p=0·074)  0·95 (0·77–1·17)
Malnutrition
Likely normal 90/595 (15%) 96/592 (16%) 0·93 (0·68–1·28) 0·66 7·12 4 0·13
Likely malnutrition 180/424 (42%) 179/418 (43%) 1·00 (0·75–1·31) 0·97 5·63 4 0·23
Subtotal  (I2=0·0%, p=0·736)  0·97 (0·79–1·19)
HIV status
Likely negative 118/660 (18%) 116/650 (18%) 1·01 (0·76–1·35) 0·93 10·52 5 0·06
Likely positive 150/286 (52%) 157/294 (53%) 0·97 (0·70–1·34) 0·83 5·02 2 0·08
Subtotal  (I2=0·0%, p=0·855)  0·99 (0·80–1·23)
Active antibiotic before ﬁrst dose 
No 203/729 (28%) 195/701 (28%) 0·98 (0·77–1·25) 0·86 7·60 5 0·18
Yes 63/281 (22%) 76/293 (26%) 0·88 (0·58–1·33) 0·54 4·09 4 0·39
Subtotal  (I2=0·0%, p=0·661)  0·95 (0·77–1·18)
Heart rate (beats per min)
<120 127/570 (22%) 116/555 (21%) 1·15 (0·84–1·56) 0·39 8·54 5 0·13
≥120 139/430 (32%) 148/432 (34%) 0·90 (0·67–1·21) 0·48 2·19 5 0·82
Subtotal  (I2=20·6%, p=0·262)  1·01 (0·82–1·25)
Blood haemoglobin
<10 g/dL 125/367 (34%) 130/371 (35%) 0·92 (0·67–1·26) 0·60 4·68 5 0·46
≥10 g/dL 119/585 (20%) 119/560 (21%) 1·01 (0·74–1·37) 0·95 8·62 5 0·13
Subtotal  (I2=0·0%, p=0·678)  0·97 (0·77–1·20)
Figure 2: Subgroup analyses for death
BM=bacterial meningitis. OR=odds ratio. 
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heterogeneity was observed in patients with either no or 
little CNS impairment or with severe CNS impairment. 
Overall, there was no evidence of any diﬀ erence in 
outcome for any of the CNS subgroups in any of the ﬁ ve 
endpoints. The eﬀ ect of HIV was explored by adjustment 
with logistic regression analysis and also by studying 
only patients with proven HIV status. However, HIV 
status did not have an eﬀ ect on dexamethasone treatment 
outcome (webappendix). We further explored the relation 
between age, HIV status, and dexamethasone treatment 
Events/total (%) OR (95% CI) p Test for heterogeneity 
between studies
Dexamethasone χ2 df pPlacebo
Favours dexamethasone  Favours placebo 
10·30·20·1 0·5 2 3 4 5 10
Consciousness level
Normal 33/288 (11%) 25/305 (8%) 1·39 (0·78–2·46) 0·26 2·76 4 0·60
Mild impairment 67/349 (19%) 79/350 (23%) 0·82 (0·55–1·21) 0·32 1·92 5 0·86
Moderate impairment 89/239 (37%) 87/213 (41%) 0·93 (0·62–1·38) 0·71 12·50 5 0·03
Severe impairment 78/137 (57%) 84/138 (61%) 0·75 (0·45–1·25) 0·27 9·90 5 0·08
Subtotal  (I2=0·0%, p=0·404)   0·91 (0·73–1·14)
CSF white cell count (cells per μL)
0–99 42/76 (55%) 34/64 (53%) 1·09 (0·53–2·25) 0·82 2·00 4 0·74
100–999 101/284 (36%) 104/280 (37%) 0·96 (0·66–1·37) 0·80 3·31 5 0·65
1000–9999 80/450 (48%) 91/487 (19%) 0·92 (0·65–1·30) 0·64 8·19 5 0·15
≥10 000 39/187 (21%) 41/162 (25%) 0·80 (0·47–1·34) 0·39 2·66 5 0·75
 Subtotal  (I2=0·0%, p=0·911)   0·93 (0·75–1·15)
CSF glucose
<20 mg 190/648 (29%) 206/632 (33%) 0·86 (0·67–1·11) 0·25 9·71 5 0·08
≥20 mg 48/284 (17%) 35/288 (12%) 1·48 (0·90–2·44) 0·12 3·17 5 0·67
Subtotal  (I2=72·4%, p=0·057)   0·96 (0·77–1·20)
CSF protein
<250 mg 36/283 (13%) 25/250 (10%) 1·39 (0·80–2·43) 0·24 2·81 5 0·73
≥250 mg 184/588 (31%) 196/607 (32%) 0·95 (0·73–1·23) 0·68 5·99 5 0·31
Subtotal  (I2=32·3%, p=0·224)   1·02 (0·80–1·29)
Pyogenic organism seen on microscopy
No 87/340 (26%) 81/319 (25%) 0·97 (0·66–1·42) 0·88 5·22 5 0·39
Yes 173/641 (27%) 186/656 (28%) 0·95 (0·73–1·22) 0·67 14·79 5 0·01
Subtotal  (I2=0·0%, p=0·929)   0·96 (0·77–1·18)
Causative organism
Unknown 55/176 (31%) 45/164 (27%) 1·29 (0·75–2·21) 0·36 5·80 5 0·33
S pneumoniae 131/383 (34%) 146/376 (39%) 0·82 (0·60–1·11) 0·20 9·15 5 0·10
N meningitidis 4/122 (3%) 4/117 (3%) 0·87 (0·23–3·27) 0·84 4·27 3 0·23
H inﬂuenzae 28/135 (21%) 37/162 (23%) 0·86 (0·49–1·51) 0·60 1·39 2 0·50
S suis 0/72 (0%) 3/65 (5%) 0·12 (0·01–2·43) 0·07 ·· ·· ··
Aerobic gram-negative bacilli 31/51 (61%) 17/37 (45%) 2·03 (0·76–5·40) 0·15 0·86 2 0·65
Other 9/52 (17%) 14/67 (21%) 0·54 (0·19–1·54) 0·24 2·59 4 0·63
Deﬁnitely not BM 12/28 (43%) 9/22 (41%) 1·25 (0·39–4·05) 0·71 0·58 1 0·45
Subtotal  (I2=7·8%, p=0·370)   0·92 (0·74–1·15)
BM conﬁrmation
Conﬁrmed 203/815 (25%) 221/824 (27%) 0·90 (0·72–1·14) 0·4 9·87 5 0·08
Probable 55/176 (31%) 45/164 (27%) 1·29 (0·75–2·21) 0·36 5·80 5 0·33
Subtotal  (I2=30·8%, p=0·229)   0·95 (0·77–1·17)
Figure 3: Subgroup analyses for death
BM=bacterial meningitis. OR=odds ratio.
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eﬀ ect (table 4). In HIV-negative adults, dexamethasone 
was associated with a reduction in death or severe 
neurological sequelae, including severe bilateral hearing 
loss (OR 0·68 [95% CI 0·48–0·95], p=0·02), death or 
any neurological sequelae, including any hearing loss 
(OR 0·67 [0·50–0·91], p=0·01), and death or severe 
bilateral hearing loss (OR 0·61 [0·42–0·89], p=0·01). 
However, this eﬀ ect of dexamethasone was not present 
in HIV-negative children, or in HIV-positive children 
and adults.
Gastrointestinal bleeding was reported in all studies: 
13 (1·3%) of 1021 patients on dexamethasone and 
19 (1·9%) of 1014 patients on placebo (p=0·14). 
Hyperglycaemia and infection by herpes simplex virus 
and varicella zoster virus were reported in some but not 
all studies.4,13,16 Hyperglycaemia was recorded by the trials 
in Malawian and European adults and was signiﬁ cantly 
associated with dexamethasone treatment (79 of 
390 [20·3%] on dexamethasone vs 60 of 376 [16·0%] on 
placebo; p=0·02). Neither infection with herpes simplex 
virus (labial infection in all) nor infection with varicella 
zoster virus were signiﬁ cantly associated with 
dexamethasone treatment. 
Dexamethasone did not signiﬁ cantly aﬀ ect mortality 
in a combined analysis with the data from other studies 
included in the Cochrane analysis8 (OR 0·88 [95% CI 
0·73–1·04], p=0·14; ﬁ gure 4).17–27,30–35 349 (18·0%) of 
1944 patients who received dexamethasone died, 
compared with 384 (19·8%) of 1939 patients who 
received placebo. There was no evidence of signiﬁ cant 
heterogeneity between the trials.
Discussion
The aim of this analysis was to establish whether any 
subgroups of patients with acute bacterial meningitis 
might beneﬁ t from adjunctive dexamethasone and thereby 
explain any diﬀ erences between individual trial results. 
Extensive exploration of 15 prespeciﬁ ed subgroups did not 
show robust evidence that a particular subgroup would 
beneﬁ t. The apparent beneﬁ t in adults aged over 55 years 
might have occurred by chance. However, it is unclear 
whether it is more likely to have occurred by chance than 
the ﬁ ndings of no beneﬁ t in other subgroups.
This analysis of 2029 patients from ﬁ ve trials showed 
that treatment with adjunctive dexamethasone did not 
signiﬁ cantly reduce mortality, neurological disability, or 
severe hearing loss in bacterial meningitis. Combination 
of these results with those from older published trials, for 
which the raw data were not obtainable, did not show any 
evidence that dexamethasone was signiﬁ cantly eﬀ ective 
in reducing these outcomes overall. However, a post-hoc 
analysis on the incidence of deafness among survivors 
suggested that adjunctive dexamethasone treatment 
reduced the rate of hearing loss (OR 0·77 [95% CI 0·60–
0·99; p=0·04), irrespective of whether patients had 
received antibiotics before dexamethasone treatment. The 
use of adjunctive dexamethasone treatment was not 
associated with an increased risk of adverse events.
Factors previously considered relevant to the decision 
to start dexamethasone treatment in patients with 
suspected or proven bacterial meningitis could not 
explain diﬀ erences in results between the ﬁ ve trials. 
These factors include duration of symptoms before 
treatment, severity of impaired consciousness at start of 
treatment, whether dexamethasone was given before or 
after antibiotics, and HIV infection status.7,36–39 Because 
the results of the prespeciﬁ ed analysis failed to show any 
signiﬁ cant heterogeneity, extensive post-hoc analyses 
were done with the inclusion of an additional deafness 
endpoint. Such analyses are usually considered 
unreliable, particularly if no statistical allowance is made 
for multiple comparisons, because of the high chance of 
a false-positive result. However, the extra analyses were 
undertaken to allow the identiﬁ cation of subgroups of 
interest for further possible study. These exploratory 
post-hoc analyses suggested a possible overall eﬀ ect on 
deafness among survivors and on death and severe 
neurological sequelae in the subgroup of HIV-negative 
HIV negative HIV positive Overall Test for heterogeneity
Adult Child Adult Child χ2 (3 df) p I²
Death 0·66 (0·42–1·02, 
0·06)
1·43 (0·96–2·12,
0·07)
1·19 (0·81–1·75, 
0·36)
0·54 (0·28–1·03, 
0·06)
0·99 (0·80–1·23, 
0·99)
10·7 0·01 72·0%
Death or severe neurological 
sequelae or bilateral severe 
deafness
0·68 (0·48–0·95, 
0·02)
1·09 (0·77–1·55, 
0·62)
1·10 (0·73–1·66, 
0·67)
0·77 (0·36–1·66, 
0·44)
0·90 (0·73–1·10, 
0·29)
4·8 0·19 37·4%
Death or any neurological 
sequelae or any hearing loss
0·67 (0·50–0·91, 
0·01)
1·09 (0·77–1·56, 
0·62)
1·15 (0·73–1·82, 
0·54)
0·77 (0·35–1·71, 
0·53)
0·88 (0·72–1·07, 
0·18)
6·0 0·11 50·1%
Death or severe bilateral 
hearing loss
0·61 (0·42–0·89, 
0·01)
1·16 (0·80–1·67, 
0·43)
1·13 (0·75–1·70, 
0·55)
0·62 (0·30–1·29, 
0·20)
0·89 (0·72–1·09, 
0·26)
8·1 0·04 28·5%
Any hearing loss in survivors 0·76 (0·52–1·13, 
0·17)
0·67 (0·42–1·07, 
0·09)
0·87 (0·46–1·63, 
0·66)
1·09 (0·37–3·19, 
0·87)
0·77 (0·59–0·99, 
0·06)
0·9 0·83 0·0%
Data are OR (95% CI, p value) unless otherwise stated. Adults were deﬁ ned as ≥15 years. HIV negative includes patients who tested negative or were likely to be negative. HIV 
positive includes those who tested positive or were likely to be positive.
Table 4: Exploratory analyses of the inﬂ uence of age and HIV infection on the treatment eﬀ ect of dexamethasone
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adults (OR 0·68 [95% CI 0·54–0·99], p=0·02). This 
apparent treatment eﬀ ect ceased to be signiﬁ cant after 
adjustment for multiple comparisons. 
This meta-analysis is, as are all meta-analyses, limited 
by the possibility that more heterogeneity exists between 
the studies than has been identiﬁ ed. If such heterogeneity 
were to exist, combining the studies would be 
inappropriate. Formal tests for heterogeneity between 
studies and between subgroups failed to show any 
convincing evidence of heterogeneity. However, such tests 
are insensitive and could miss important eﬀ ects. We have 
therefore explored the data exhaustively for relevant 
subgroups of patients that could reveal possible causes of 
heterogeneity, although little such evidence was found. 
On the basis of previous meta-analyses,9,10 the 
administration of dexamethasone to children with 
H inﬂ uenzae type b meningitis before the start of 
antibiotic therapy is thought to reduce the incidence of 
deafness. However, we found no evidence of a beneﬁ t of 
adjunctive dexamethasone in all children or in any 
subgroup of children with this infection. 
In summary, these data indicate that patients with 
bacterial meningitis neither beneﬁ t from nor are harmed 
by treatment with adjunctive dexamethasone. Despite an 
individual patient data meta-analysis of more than 
2000 patients, we have been unable to determine 
conclusively whether a subgroup of patients might beneﬁ t. 
To establish with certainty whether dexamethasone has a 
place in the treatment of adult patients with bacterial 
meningitis, a large multinational randomised controlled 
trial would be necessary. This represents a formidable 
challenge and one that is not likely to be met for many years. 
In the meantime, we suggest the beneﬁ t of adjunctive 
dexamethasone for all or any subgroup of patients with 
bacterial meningitis remains unproven and there is little 
support for its routine use in the treatment of this disease.
Events/total (%) OR (95% CI)
Dexamethasone Placebo
Favours dexamethasone   Favours placebo  
1 0·3 0·2 0·1 0·5 2 3 4 5 10 
Current meta-analysis
Europe16 11/157 (7%) 21/144 (15%) 0·44 (0·20–0·95)
Malawi (child)15 92/305 (30%) 89/293 (30%) 0·99 (0·70–1·40)
Vietnam13 22/215 (10%) 27/214 (13%) 0·79 (0·43–1·44)
Malawi (adult)14 122/233 (52%) 113/232 (49%) 1·16 (0·80–1·67)
South America randomisation schedule 112 14/50 (28%) 16/76 (21%) 1·46 (0·64–3·34)
South America randomisation schedule 212 9/59 (15%) 10/51 (20%) 0·74 (0·27–1·99)
Subtotal  (I2=24·7%, p=0·249) 270/1019 (26%) 276/1010 (27%) 0·96 (0·78–1·19)
Other studies from 2007 Cochrane review8 
Bennett (1963)30 16/38 (42%) 22/47 (47%) 0·83 (0·35–1·96)
DeLemos (1969)21 2/54 (4%) 1/63 (2%) 2·38 (0·21–27·05)
Belsey (1969)17 2/43 (5%) 1/43 (2%) 2·05 (0·18–23·48)
Bademosi (1979)18 11/28 (39%) 12/24 (50%) 0·65 (0·21–1·95)
Girgis (1989)22 20/210 (10%) 42/219 (19%) 0·44 (0·25–0·78)
Lebel (1989)32 0/31 1/31 (3%) 0·32 (0·01–8·23)
Odio (1991)25 1/52 (2%) 1/49 (2%) 0·94 (0·06–15·47)
King (1994)31 0/50 1/51 (2%) 0·33 (0·01–8·38)
Ciana (1995)20 8/34 (24%) 12/36 (33%) 0·62 (0·21–1·76)
Wald (1995)33 1/69 (1%) 0/74 3·26 (0·13–81·45)
Kanra (1995)23 2/29 (7%) 1/27 (4%) 1·93 (0·16–22·55)
Qazi (1996)26 12/48 (25%) 5/41 (12%) 2·40 (0·77–7·51)
Bhaumik (1998)19 1/14 (7%) 3/16 (19%) 0·33 (0·03–3·64)
Lebel (1988)24* 0/51 1/49 (2%) 0·31 (0·01–7·89)
Thomas (1999)27 3/31 (10%) 5/29 (17%) 0·51 (0·11–2·38)
Lebel (1988)24† 0/51 0/49 ··
Schaad (1993)35 0/60 0/55 ··
Kilpi (1995)34 0/32 0/26 ··
Subtotal  (I2=0·0%, p=0·636) 79/925 (9%) 108/929 (12%) 0·69 (0·50–0·97)
Overall (I2=4·9%, p=0·396) 349/1944 (18%) 384/1939 (20%) 0·88 (0·73–1·04)
Figure 4: Eﬀ ect of adjunctive dexamethasone therapy on death
Trials included in the rest of this study12–16 and other studies 17–27,30–35 included in the Cochrane systematic review8 are shown. OR=odds ratio. *Study 1 in Lebel.24 †Study 2 
in Lebel.24
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